This is a nice follow-up to the PeterMac podcast Marnie posted yesterday. It also helps to confirm Don Pescado's claim that "the Science is Coming".
In this Lancet comment article by Louise Kostos & Declan Murphy, both at PeterMac in AU, they update the current treatment options/recommendations for metastatic, hormone-sensitive PCa in light of the Phase III results from the CHART trial comparing ADT plus the new ARI agent rezvilutamide vs ADT plus bicalutamide - in this case for patients with high-volume, metastatic, hormone-sensitive disease.
Once again, the people at PeterMac emphasize the lack of the universal application of combination therapy (ADT + ARIs) for many PCa patients. They also restate the clear evidence for the superiority of PSMA-PET in the initial determination of disease volume and restaging those initially staged with conventional bone/CT scans.
The Lancet PeterMac Comment article is here:
Treatment options for metastatic hormone-sensitive prostate cancer - The Lancet Oncology - Comment by Louise Kostos & Declan G Murphy, Published: September 05, 2022
thelancet.com/journals/lano...
A MedPage Today article on the trial results here:
Rezvilutamide Bests Bicalutamide in Metastatic Prostate Cancer — Combined with ADT, the androgen-receptor inhibitor significantly improved OS, radiographic PFS - by Mike Bassett, Staff Writer, MedPage Today, September 7, 2022
medpagetoday.com/hematology...
And the actual CHART III trial publication here:
Rezvilutamide versus bicalutamide in combination with androgen-deprivation therapy in patients with high-volume, metastatic, hormone-sensitive prostate cancer (CHART): a randomised, open-label, phase 3 trial - The Lancet Oncology, Published: September 05, 2022
thelancet.com/journals/lano...
Keep it Safe and Well,
Ciao - K9 terror